Novel Inhalation Formulation Of Colistin And Combination Therapy Against Gram-negative 'superbugs'
Funder
National Health and Medical Research Council
Funding Amount
$513,896.00
Summary
Respiratory infections caused by multidrug-resistant Gram-negative bacteria are major health problems for Australians. Colistin is the last-resort defense in most cases. However, parenteral administration of colistin will cause serious side effects. This proposal applies an interdisciplinary approach using aerosol particle engineering, functional lung imaging and antimicrobial pharmacology to develop and characterise novel inhaled powder formulations of colistin and its rational combinations.